Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 105 Digital Dr NOVATO CA 94949-8703 |
Tel: | N/A |
Website: | https://www.biomarin.com |
IR: | See website |
Key People | ||
Alexander Hardy President, Chief Executive Officer, Director | Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance | Henry J. Fuchs President - Worldwide Research and Development |
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer | G. Eric Davis Executive Vice President, Secretary, Chief Legal Officer | Jeffrey Robert Ajer Executive Vice President, Chief Commercial Officer |
Cristin Hubbard Executive Vice President, Chief Commercial Officer | Erin Burkhart Group Vice President, Chief Accounting Officer |
Business Overview |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease. |
Financial Overview |
For the three months ended 31 March 2024, Biomarin Pharmaceutical Inc revenues increased 9% to $648.8M. Net income increased 74% to $88.7M. Revenues reflect Voxzogo segment increase of 74% to $152.9M, Palynziq1 segment increase of 21% to $75.7M, Europe segment increase of 22% to $195.7M, United States segment increase of 16% to $193M. Net income benefited from Equity investment impairment decrease from $12.6M (expense) to $0K. |
Employees: | 3,401 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $14,768M as of Mar 31, 2024 |
Annual revenue (TTM): | $2,472M as of Mar 31, 2024 |
EBITDA (TTM): | $282.53M as of Mar 31, 2024 |
Net annual income (TTM): | $205.46M as of Mar 31, 2024 |
Free cash flow (TTM): | $163.21M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $41.38M as of Mar 31, 2024 |
Shares outstanding: | 189,879,803 as of Apr 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |